We are testing the activity of the chemotherapy agent gemcitabine in patients with recurrent or refractory Hodgkin's disease or non-Hodgkin's lymphoma. Patients may have either disease and must have recurred or progressed after standard treatments. Patients will receive treatment until the maximum benefit is achieved, usually around six months of treatment.
Showing the most recent 10 out of 589 publications